Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.

@article{Zhang2012IntravitrealBF,
  title={Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.},
  author={Han Zhang and Zhe-li Liu and Peter P Sun and Feng Gu},
  journal={American journal of ophthalmology},
  year={2012},
  volume={153 2},
  pages={300-306.e1}
}
PURPOSE To evaluate the visual and anatomic outcomes of intravitreal bevacizumab in patients with subfoveal idiopathic choroidal neovascularization (CNV). DESIGN Prospective, nonrandomized, interventional case series. METHODS Forty patients with subfoveal idiopathic CNV were included in this clinical trial. Their eyes were treated with a single intravitreal injection of 1.25 mg bevacizumab followed by as-needed dosing indicated by the presence and recurrence of intraretinal edema… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

A systematic review on the effect of bevacizumab in exudative age - related macular degeneration

  • WM Chan, TY Lai, DT Liu, DS Lam
  • Graefes Arch Clin Exp Ophthalmol
  • 2009

Similar Papers

Loading similar papers…